Asian Biomedicine最新文献

{"title":"Comparison of endoscopic resection, laparoscopic resection, and laparoscopic endoscopic cooperative surgery in esophageal or gastric subepithelial lesions in a Thai medical school.","authors":"Phuphat Vongwattanakit, Voranaddha Vacharathit, Kasaya Tantiphlachiva, Mawin Vongsaisuwon, Chadin Tharavej, Sopark Manasnayakorn, Pornpol Palanusorn","doi":"10.2478/abm-2025-0026","DOIUrl":"10.2478/abm-2025-0026","url":null,"abstract":"<p><strong>Background: </strong>Esophageal and gastric subepithelial lesions (SELs) are increasingly identified in routine endoscopic evaluations, necessitating optimal resection strategies. Minimally invasive techniques, including endoscopic resection (ER), laparoscopic resection (LR), and laparoscopic-endoscopic cooperative surgery (LECS), have distinct advantages. The present study compares the outcomes of these techniques.</p><p><strong>Objective: </strong>To compare the clinical outcomes of ER, LR, and LECS in the management of esophageal or gastric SELs at King Chulalongkorn Memorial Hospital.</p><p><strong>Methods: </strong>A retrospective review was conducted on patients undergoing ER, LR, or LECS for esophageal and gastric SELs from January 2012 to August 2022. The primary outcome was the complete resection rate. Secondary outcomes included success rates, complications, and length of hospital stay. Statistical significance was set at <i>P</i> < 0.05.</p><p><strong>Results: </strong>Among 42 patients, 11 (26.2%) underwent ER, 12 (28.6%) underwent LR, and 19 (45.2%) underwent LECS. Complete resection was significantly higher in LR (100%) and LECS (84.2%) than ER (45.5%) (<i>P</i> = 0.033). Delayed bleeding occurred in 18.2% of ER cases (<i>P</i> = 0.052). Hospital stay was shortest in ER (3.9 d) and longest in LR (9.3 d) (<i>P</i> = 0.877).</p><p><strong>Conclusion: </strong>While all techniques had high success rates, ER had the lowest complete resection rate and the highest bleeding risk. LR ensured complete resection but required longer hospitalization. LECS provided a balance between oncologic efficacy and safety. Surgical planning should be tailored based on tumor characteristics and surgical expertise.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"209-217"},"PeriodicalIF":0.9,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Entanglement between pharmacy/pharmaceutical education and cancer? A bibliometric answer.","authors":"Siyuan Peng, Wenhao Wang, Rui Luo, Xiye Wang, Jiayue Huang, Xin Pan, Zhengwei Huang","doi":"10.2478/abm-2025-0024","DOIUrl":"10.2478/abm-2025-0024","url":null,"abstract":"<p><strong>Background: </strong>The growing role of pharmacists in cancer care highlights the need to understand research trends linking pharmaceutical education and oncology.</p><p><strong>Objective: </strong>To quantitatively investigate the bibliometric status of the entanglement between pharmacy/pharmaceutical education and cancer-related issues, providing feasible information and suggestions for the developmental basis and research hotspots.</p><p><strong>Methods: </strong>Bibliometric analysis was performed using the Web of Science Core Collection. Boolean operations (BO) were used to set up the literature query set. The literature published between 1985 and 2022 was screened for the types of \"article\" and \"review.\" The citation analysis and research hotspot extraction were performed using the \"analyze results\" and \"citation report\" functions of Clarivate Analytics.</p><p><strong>Results: </strong>The bibliometric analysis of 722 relevant papers showed that the global interest in the topic is increasing and the collaboration between countries is quite active. The extraction results showed that guidelines for cancer therapy, palliative care and pain management, pharmacy staff's attitudes and knowledge, and adherence to chemotherapy were the main research hotspots and that these have been long-term discussed.</p><p><strong>Conclusion: </strong>Conducting a bibliometric study to analyze the overall publication status, developmental basis, and research hotspots will reveal the logical entanglement of the existing academic research between pharmacy/pharmaceutical education and cancer, and will provide a reference for academic development in the educational and oncological community.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"189-195"},"PeriodicalIF":0.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can transcutaneous bilirubin levels obtained from covered skin replace serum bilirubin measurement in neonates undergoing phototherapy?","authors":"M Fatih Ozden, Dilek Kahvecioglu, Melda Tas, Aslihan Kose Cetinkaya, Ahmet Oktem","doi":"10.2478/abm-2025-0025","DOIUrl":"10.2478/abm-2025-0025","url":null,"abstract":"<p><strong>Background: </strong>Transcutaneous bilirubinometers provide a non-invasive method to estimate total serum bilirubin (TSB) using multiwavelength reflectance. However, their accuracy during phototherapy (PT) remains controversial due to decreased dermal bilirubin.</p><p><strong>Objective: </strong>To assess the correlation between TSB and transcutaneous bilirubin (TcB) measured from covered and exposed skin areas before, during, and after PT.</p><p><strong>Methods: </strong>In this prospective study, 70 neonates undergoing PT were assessed. TcB measurements were obtained from the exposed sternum and the forehead, which were covered with an aluminum-coated radiopaque patch. TSB and TcB values were measured before PT, at 24 h during treatment, and 8 h post-treatment. The agreement between TSB and TcB values was evaluated using the intraclass correlation coefficient (ICC).</p><p><strong>Results: </strong>TcB values of covered skin showed significant correlation with TSB at all-time points (ICC = 0.665 for pre-PT, ICC = 0.520 at 24 h, and ICC = 0.537 for post-treatment). TcB values of exposed skin showed poor correlation during and after PT. Mean differences between covered TcB and TSB remained within acceptable limits (<1 mg/dL).</p><p><strong>Conclusion: </strong>TcB measurements from covered skin offer a reliable, non-invasive alternative to serum bilirubin levels in neonates receiving PT, reducing the need for repeated blood draws.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"183-189"},"PeriodicalIF":0.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen.","authors":"Pannathorn Nakaphan, Noppacharn Uaprasert","doi":"10.2478/abm-2025-0021","DOIUrl":"10.2478/abm-2025-0021","url":null,"abstract":"<p><strong>Background: </strong>Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in diffuse large B-cell lymphoma (DLBCL) patients undergoing rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone every 21 d (R-CHOP-21) chemotherapy varies based on physician discretion.</p><p><strong>Objectives: </strong>The present study aims to investigate the impact of primary G-CSF prophylaxis on febrile neutropenia (FN) and other outcomes in DLBCL patients receiving R-CHOP-21 in real-world practice.</p><p><strong>Methods: </strong>Medical records of 103 newly diagnosed DLBCL patients, aged 18-80 years, were retrospectively analyzed. Seventy-four patients received primary G-CSF prophylaxis (prophylaxis group), while 29 patients did not receive prophylaxis (non-prophylaxis group). The occurrence of FN and other outcomes was compared between the two groups.</p><p><strong>Results: </strong>The prophylaxis group had older patients (median ± interquartile ranges [IQR], 63 ± 12 years vs. 50 ± 15 years, <i>P</i> < 0.001). The incidence of FN after the first R-CHOP was not statistically significant between groups (8.3% vs. 17.2%, <i>P</i> = 0.177). However, FN events were significantly higher in non-prophylaxis cycles (7.40%) compared with prophylaxis cycles (2.70%) (<i>P</i> = 0.027). Cumulative FN events were lower in the prophylaxis group (14.9%) than in the non-prophylaxis group (27.6%) (<i>P</i> = 0.134). FN-free survival was not significantly different between prophylaxis and non-prophylaxis groups (hazard ratio [HR], 0.48; 95% confidence interval [95%CI], 0.17-1.35), while primary G-CSF prophylaxis significantly improved event-free survival (HR, 0.36; 95%CI, 0.16-0.84).</p><p><strong>Conclusions: </strong>Primary G-CSF prophylaxis may reduce the risk of FN in DLBCL patients undergoing R-CHOP-21 treatment. The present study highlights the importance of primary G-CSF prophylaxis, especially for those at high risk of FN.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"165-173"},"PeriodicalIF":0.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of febrile neutropenia in diffuse large B-cell lymphoma treated with R-CHOP.","authors":"","doi":"10.2478/abm-2025-0020","DOIUrl":"10.2478/abm-2025-0020","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"164"},"PeriodicalIF":0.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a methodology for the volume estimation of the prefrontal cortical subfields in very pre-term infants using magnetic resonance imaging and stereology.","authors":"Faten Aldhafeeri","doi":"10.2478/abm-2025-0023","DOIUrl":"10.2478/abm-2025-0023","url":null,"abstract":"<p><strong>Background: </strong>The prefrontal cortex (PFC) is vital for cognitive and emotional functions and is vulnerable to disruptions in preterm infants. Reliable volume estimation methods are needed to study its development.</p><p><strong>Objective: </strong>To develop and validate a novel method for estimating the volume of PFC subfields in very preterm infants using magnetic resonance imaging (MRI) combined with stereological techniques. The method was designed to achieve a coefficient of error (CE) below 5%.</p><p><strong>Methods: </strong>Five preterm infants born before 28 weeks of gestation were scanned using a 1.5-Tesla MRI scanner. The points of intersection between the grid and structure boundaries, in addition to the points in each slice, were counted using in-house software (Easy Measure).</p><p><strong>Results: </strong>The shape coefficient for each subfield of the prefrontal cortex was calculated, which yielded coefficients of 4.5, 6.1, 6.4, and 6.5 for dorsolateral, dorsomedial, orbitolateral, and orbitomedial PFC regions, respectively. For the dorsolateral prefrontal cortex, a grid size of 4 × 4 pixels and a 0.2 cm slice gap for the dorsomedial prefrontal cortex (DMPFC), a grid size of 5 × 5 pixels and a 0.1 cm slice gap for the orbitolateral PFC, a grid size of 5 × 5 pixels and a 0.3 cm slice gap, and a grid size of 5 × 5 pixels and 0.1 cm slice gap for the DMPFC resulted in <5% CE.</p><p><strong>Conclusion: </strong>This methodology offers new insights into the neurodevelopmental effects of preterm birth and has potential applications in the early detection of neurodevelopmental disorders. Its precision, reliability, and non-invasive nature make it suitable for longitudinal studies and contribute to neonatal neuroimaging and neurodevelopmental research.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"174-182"},"PeriodicalIF":0.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the genetics and neurology: an overview of adult neurogenetics.","authors":"Pasin Hemachudha, Prakit Anukoolwittaya, Thanakit Pongpitakmetha, Yutthana Joyjinda, Chanida Ruchisrisarod, Abhinbhen W Saraya, Wanakorn Rattanawong, Poosanu Thanapornsungsuth, Thiravat Hemachudha","doi":"10.2478/abm-2025-0022","DOIUrl":"10.2478/abm-2025-0022","url":null,"abstract":"<p><p>Neurogenetics investigates the genetic basis of neurological disorders. It encompasses conditions ranging from neurodegenerative diseases with predominantly polygenic risk genes, such as Alzheimer's and Parkinson's, to monogenic diseases and repeated expansion disorders within movement and neuromuscular disorders, such as Friedreich ataxia and muscular dystrophies. Significant advances in recent years that have revolutionized our understanding of disease mechanisms and paved the way for personalized medicine approaches are due to the field of neurogenetics, with its intricate relationship both with clinical and genetic research. Therefore, all neurologists, even in resource-limited settings, are aware of the critical genetic basis; standard molecular diagnostic techniques such as next-generation sequencing, whole exome, and whole genome sequencing; and possible therapeutic modalities of their field. This review will also touch on elements of the neurogenetic clinic in tertiary care, ethical considerations, and insight into ongoing research that would help improve patient care and enhance clinical outcomes.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 4","pages":"196-208"},"PeriodicalIF":0.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of intravenous immunoglobulin and plasma exchange in hospital-acquired infections of autoimmune encephalitis in a tertiary care center.","authors":"Totsapol Surawattanawong, Akarin Hiransuthikul, Panthicha Katasrila, Thiravat Hemachudha, Abhinbhen W Saraya","doi":"10.2478/abm-2025-0018","DOIUrl":"10.2478/abm-2025-0018","url":null,"abstract":"<p><strong>Background: </strong>The prevailing approach for the acute-phase treatment of autoimmune encephalitis (AIE) is currently the administration of intravenous immunoglobulin (IVIG) or plasma exchange (PLEX), in conjunction with high-dose corticosteroids. Despite this, there is still no definitive evidence on the risks and benefits of IVIG vs. PLEX in terms of treatment-related complications.</p><p><strong>Objectives: </strong>The primary objective of this study was to determine the differences in the cumulative incidence of hospital-acquired infections (HAIs) in patients diagnosed with AIE, who received either IVIG or PLEX. The secondary objectives were to explore the differences in the duration of hospitalization and levels of disability.</p><p><strong>Methods: </strong>Patients who were hospitalized at the King Chulalongkorn Memorial Hospital, Thailand, due to AIE, were aged ≥15 years, and had received either IVIG or PLEX during their hospitalization from January 2015 to December 2020 were included in the study. The modified Rankin scale (mRS) was utilized to evaluate the degree of disability at admission and discharge.</p><p><strong>Results: </strong>Among the 44 patients included in the study, 10 (22.7%) received PLEX and 34 (77.3%) received IVIG. Those who received IVIG were significantly less likely to have HAIs (14.7% vs. 50.0%, <i>P</i> = 0.03) and had a significantly shorter duration of hospitalization (median [IQR] 12.0 [6.0 - 23.0] vs. 25.0 [21.0 - 49.0] d, <i>P</i> = 0.01) compared to those who received PLEX. Primary septicemia was the most commonly observed cause of infection in both groups. There were no significant differences in mRS at discharge, changes in mRS between admission and discharge, and the total direct cost of hospitalization between the two groups.</p><p><strong>Conclusions: </strong>The utilization of IVIG is associated with a diminished occurrence of nosocomial infections, leading to shorter hospitalization and potential cost benefits. Our findings propose that IVIG may represent a more beneficial therapeutic alternative for AIE patients compared with PLEX.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 3","pages":"147-153"},"PeriodicalIF":0.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and public health measures to cope with respiratory syncytial virus infection.","authors":"","doi":"10.2478/abm-2025-0014","DOIUrl":"10.2478/abm-2025-0014","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 3","pages":"114-115"},"PeriodicalIF":0.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis.","authors":"Napaporn Chantasrisawad, Wicharn Boonjindasup, Thanyawee Puthanakit, Surasith Chaithongwongwatthana","doi":"10.2478/abm-2025-0015","DOIUrl":"10.2478/abm-2025-0015","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is a major respiratory pathogen that particularly affects infants under 6 months, premature infants, and those with congenital heart disease (CHD) or chronic lung disease. In 2019, there was estimated 3.6 million hospital admissions among children under 5 years of age due to RSV-related lower respiratory tract infection (RSV-LRTI), with more than 26,000 deaths. For decades, monthly palivizumab injection has provided passive immunization for high-risk infants and has demonstrated efficacy in reducing RSV-related hospitalizations, while breastfeeding has been known to protect against severe RSV-LRTI. Recent advances aiming to reduce severe RSV-LRTI, that is, bronchiolitis and pneumonia, include maternal RSV immunization and long-acting monoclonal antibodies for infants. Bivalent non-adjuvanted RSV vaccine (Abrysvo®), RSVPreF, administered during pregnancy (gestational age 24-36 weeks) transfers protective RSV IgG antibodies across the placenta with high cord-to-maternal ratio at ~1.5. Studies have shown that maternal immunization significantly reduced medically attended severe RSV-associated LRTI in infants, with an efficacy of 81.8% at 90 days and 69.4% at 180 days after birth, respectively. For medically attended RSV-associated LRTI, the efficacy was 57.1% at 90 days and 51.3% at 180 days. Additionally, long-acting RSV monoclonal antibodies (Nirsevimab) provide season-long protection with a single dose for infants during the first RSV season, reducing both medically attended RSV-LRTI and hospitalizations by approximately 70%-80% in infants during their first RSV season. Consequently, in 2024, the Strategic Advisory Group of Experts (SAGE) recommended that countries introduce maternal RSVPreF vaccination and/or RSV monoclonal antibodies for infant RSV prevention. Many countries have already adopted these interventions, demonstrating cost-effectiveness of monoclonal antibodies.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 3","pages":"116-130"},"PeriodicalIF":0.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}